The involvement of GABAergic system in the antidepressant-like effect of agmatine.
Agmatine
/ pharmacology
Animals
Antidepressive Agents
/ pharmacology
Depression
/ drug therapy
Female
GABA Agonists
/ pharmacology
GABA Antagonists
/ pharmacology
GABAergic Neurons
/ drug effects
Hindlimb Suspension
/ adverse effects
Mice
Receptors, GABA
/ physiology
gamma-Aminobutyric Acid
/ physiology
Agmatine
Antidepressant
GABA
Ketamine
Tail suspension test
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
26
11
2019
accepted:
13
05
2020
pubmed:
25
5
2020
medline:
12
8
2021
entrez:
25
5
2020
Statut:
ppublish
Résumé
Considering the involvement of GABAergic system in the action of the fast-acting antidepressant ketamine, and that agmatine may exert an antidepressant-like effect through mechanisms similar to ketamine, the purpose of the present study was to evaluate the involvement of GABA
Identifiants
pubmed: 32447465
doi: 10.1007/s00210-020-01910-5
pii: 10.1007/s00210-020-01910-5
doi:
Substances chimiques
Antidepressive Agents
0
GABA Agonists
0
GABA Antagonists
0
Receptors, GABA
0
gamma-Aminobutyric Acid
56-12-2
Agmatine
70J407ZL5Q
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1931-1939Subventions
Organisme : CNPq
ID : 449436/2014-4
Pays : International
Organisme : CNPq
ID : 421143/2018-5
Pays : International
Organisme : CNPq
ID : 158126/2018-1
Pays : International
Références
Abdallah CG, Salas R, Jackowski A, Baldwin P, Sato JR, Mathew SJ (2015) Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol 29:591–595
pubmed: 25122038
doi: 10.1177/0269881114544776
Andrade C (2017) Ketamine for depression, 5: potential pharmacokinetic and pharmacodynamic drug interactions. J Clin Psychiatry 78:858–861
doi: 10.4088/JCP.17f11802
Arranz B, Cowburn R, Eriksson A, Vestling M, Marcusson J (1992) Gamma-aminobutyric acid-B (GABAB) binding sites in postmortem suicide brains. Neuropsychobiology 26:33–36
pubmed: 1335560
doi: 10.1159/000118893
Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91–95
pubmed: 21677641
pmcid: 3172695
doi: 10.1038/nature10130
Banasr M, Lepack A, Fee C et al (2017) Characterization of GABAergic marker expression in the chronic unpredictable stress model of depression. Chronic Stress (Thousand Oaks) 1:30
Bergfeld IO, Mantione M, Figee M, Schuurman PR, Lok A, Denys D (2018) Treatment-resistant depression and suicidality. J Affect Disord 235:362–367
pubmed: 29665520
doi: 10.1016/j.jad.2018.04.016
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354
pubmed: 10686270
doi: 10.1016/S0006-3223(99)00230-9
Bettio LE, Cunha MP, Budni J et al (2012) Guanosine produces an antidepressant-like effect through the modulation of NMDA receptors, nitric oxide-cGMP and PI3K/mTOR pathways. Behav Brain Res 234:137–148
pubmed: 22743004
doi: 10.1016/j.bbr.2012.06.021
Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Boorman E, M Matthews P, J Cowen P (2008) Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 11:255–260
pubmed: 17625025
doi: 10.1017/S1461145707007924
Biggio G, Concas A, Corda MG, Giorgi O, Sanna E, Serra M (1990) GABAergic and dopaminergic transmission in the rat cerebral cortex: effect of stress, anxiolytic and anxiogenic drugs. Pharmacol Ther 48:121–142
pubmed: 1981393
doi: 10.1016/0163-7258(90)90077-F
Celada P, Puig M, Amargos-Bosch M et al (2004) The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29:252–265
pubmed: 15309042
pmcid: 446220
Choudary PV, Molnar M, Evans SJ et al (2005) Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 102:15653–15658
Clevenger SS, Malhotra D, Dang J, Vanle B, IsHak WW (2018) The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder. Ther Adv Psychopharmacol 8:49–58
pubmed: 29344343
doi: 10.1177/2045125317737264
Cross JA, Cheetham SC, Crompton MR, Katona CLE, Horton RW (1988) Brain GABAB binding sites in depressed suicide victims. Psychiatry Res 26:119–129
pubmed: 2853398
doi: 10.1016/0165-1781(88)90066-2
Cunha MP, Pazini FL, Ludka FK, Rosa JM, Oliveira Á, Budni J, Ramos-Hryb AB, Lieberknecht V, Bettio LEB, Martín-de-Saavedra MD, López MG, Tasca CI, Rodrigues ALS (2015) The modulation of NMDA receptors and L-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test. Amino Acids 47:795–811
pubmed: 25555469
doi: 10.1007/s00726-014-1910-0
Dixit MP, Thakre PP, Pannase AS, Aglawe MM, Taksande BG, Kotagale NR (2014) Imidazoline binding sites mediates anticompulsive-like effect of agmatine in marble-burying behavior in mice. Eur J Pharmacol 732:26–31
pubmed: 24657463
doi: 10.1016/j.ejphar.2014.02.045
Farzin D, Mansouri N (2006) Antidepressant-like effect of harmane and other beta-carbolines in the mouse forced swim test. Eur Neuropsychopharmacol 6:324–328
doi: 10.1016/j.euroneuro.2005.08.005
Freitas AE, Bettio LE, Neis VB et al (2014) Agmatine abolishes restraint stress-induced depressive-like behavior and hippocampal antioxidant imbalance in mice. Prog Neuro-Psychopharmacol Biol Psychiatry 50:143–150
doi: 10.1016/j.pnpbp.2013.12.012
Gao Y, Zhou JJ, Zhu Y, Wang L, Kosten TA, Zhang X, Li DP (2017) Neuroadaptations of presynaptic and postsynaptic GABAB receptor function in the paraventricular nucleus in response to chronic unpredictable stress. Br J Pharmacol 174:2929–2940
pubmed: 28635080
pmcid: 5554316
doi: 10.1111/bph.13924
Gawali NB, Bulani VD, Chowdhury AA, Deshpande PS, Nagmoti DM, Juvekar AR (2016) Agmatine ameliorates lipopolysaccharide induced depressive-like behaviour in mice by targeting the underlying inflammatory and oxido-nitrosative mediators. Pharmacol Biochem Behav 149:1–8
pubmed: 27453424
doi: 10.1016/j.pbb.2016.07.004
Gawali NB, Bulani VD, Gursahani MS, Deshpande PS, Kothavade PS, Juvekar AR (2017) Agmatine attenuates chronic unpredictable mild stress-induced anxiety, depression-like behaviours and cognitive impairment by modulating nitrergic signalling pathway. Brain Res 1663:66–77
pubmed: 28302445
doi: 10.1016/j.brainres.2017.03.004
Glennon RA, Dukat M, Grella B, Hong SS, Costantino L, Teitler M, Smith C, Egan C, Davis K, Mattson MV (2000) Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend 60:121–132
pubmed: 10940539
doi: 10.1016/S0376-8716(99)00148-9
Gomez AF, Barthel AL, Hofmann SG (2018) Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother 19:883–894
pubmed: 29806492
pmcid: 6097846
doi: 10.1080/14656566.2018.1472767
Gray JA, Green AR (1987) Increased GABAB receptor function in mouse frontal cortex after repeated administration of antidepressant drugs or electroconvulsive shocks. Br J Pharmacol 92:357–362
pubmed: 2823949
pmcid: 1853662
doi: 10.1111/j.1476-5381.1987.tb11331.x
Hardeveld F, Spijker J, De Graaf R et al (2013) Recurrence of major depressive disorder and its predictors in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol Med 43:39–48
pubmed: 23111147
doi: 10.1017/S0033291712002395
Heinzel A, Steinke R, Poeppel TD, Grosser O, Bogerts B, Otto H, Northoff G (2008) S-ketamine and GABA-A-receptor interaction in humans: an exploratory study with I-123-iomazenil SPECT. Hum Psychopharmacol 23:549–554
pubmed: 18546441
doi: 10.1002/hup.960
Hill DR (1985) GABAB receptor modulation of adenylate cyclase activity in rat brain slices. Br J Pharmacol 84:249–257
pubmed: 2579700
pmcid: 1987231
Kaster MP, Gadotti VM, Calixto JB, Santos ARS, Rodrigues ALS (2012) Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology 62:419–426
pubmed: 21867719
doi: 10.1016/j.neuropharm.2011.08.018
Korf J, Venema K (1983) Desmethylimipramine enhances the release of endogenous GABA and other neurotransmitter amino acids from the rat thalamus. J Neurochem 40:946–950
pubmed: 6131937
doi: 10.1111/j.1471-4159.1983.tb08078.x
Krystal JH, Perry EB Jr, Gueorguieva R et al (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62:985–994
pubmed: 16143730
doi: 10.1001/archpsyc.62.9.985
Song C, Leonard BE (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29:627–647
pubmed: 15925697
doi: 10.1016/j.neubiorev.2005.03.010
Li NX, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959–964
pubmed: 20724638
pmcid: 3116441
doi: 10.1126/science.1190287
Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, Li XY, Aghajanian G, Duman RS (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69:754–761
pubmed: 21292242
pmcid: 3068225
doi: 10.1016/j.biopsych.2010.12.015
Luscher B, Fuchs T (2015) GABAergic control of depression-related brain states. Adv Pharmacol 73:97–144
pubmed: 25637439
pmcid: 4784429
doi: 10.1016/bs.apha.2014.11.003
Luscher B, Shen Q, Sahir N (2011) The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 16:383–406
pubmed: 21079608
doi: 10.1038/mp.2010.120
Magni G, Garreau M, Orofiamma B et al (1989) Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics. Neuropsychobiology 20:126–131
pubmed: 2668780
doi: 10.1159/000118485
Mathew SJ, Charney DS (2009) Publication bias and the efficacy of antidepressants. Am J Psychiatry 166:140–145
pubmed: 19188290
doi: 10.1176/appi.ajp.2008.08071102
McCarson KE, Duric V, Reisman SA et al (2006) GABA(B) receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants. Brain Res 1068:109–117
pubmed: 16368079
doi: 10.1016/j.brainres.2005.11.015
Meylan EM, Breuillaud L, Seredenina T et al (2016) Involvement of the agmatinergic system in the depressive-like phenotype of the Crtc1 knockout mouse model of depression. Transl Psychiatry 6:1–11
doi: 10.1038/tp.2016.116
Mohler H (2012) The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 62:42–53
pubmed: 21889518
doi: 10.1016/j.neuropharm.2011.08.040
Moretti M, Neis VB, Matheus FC, Cunha MP, Rosa PB, Ribeiro CM, Rodrigues ALS, Prediger RD (2015) Effects of agmatine on depressive-like behavior induced by intracerebroventricular administration of 1-methyl-4-phenylpyridinium (MPP(+)). Neurotox Res 28:222–231
pubmed: 26156429
doi: 10.1007/s12640-015-9540-1
Muir JK, Lobner D, Monyer H, Choi DW (1996) GABAA receptor activation attenuates excitotoxicity but exacerbates oxygen-glucose deprivation-induced neuronal injury in vitro. J Cereb Blood Flow Metab 16:1211–1218
pubmed: 8898693
doi: 10.1097/00004647-199611000-00015
Neis VB, Manosso LM, Moretti M, Freitas AE, Daufenbach J, Rodrigues ALS (2014) Depressive-like behavior induced by tumor necrosis factor-alpha is abolished by agmatine administration. Behav Brain Res 261:336–344
pubmed: 24406719
doi: 10.1016/j.bbr.2013.12.038
Neis VB, Bettio LEB, Moretti M, Rosa PB, Ribeiro CM, Freitas AE, Gonçalves FM, Leal RB, Rodrigues ALS (2016a) Acute agmatine administration, similar to ketamine, reverses depressive-like behavior induced by chronic unpredictable stress in mice. Pharmacol Biochem Behav 150-151:108–114
pubmed: 27743829
doi: 10.1016/j.pbb.2016.10.004
Neis VB, Moretti M, Bettio LE et al (2016b) Agmatine produces antidepressant-like effects by activating AMPA receptors and mTOR signaling. Eur Neuropsychopharmacol 26:959–971
pubmed: 27061850
doi: 10.1016/j.euroneuro.2016.03.009
Neis VB, Rosa PB, Olescowicz G, Rodrigues ALS (2017) Therapeutic potential of agmatine for CNS disorders. Neurochem Int 108:318–331
pubmed: 28522414
doi: 10.1016/j.neuint.2017.05.006
Neis VB, Bettio LB, Moretti M, Rosa PB, Olescowicz G, Fraga DB, Gonçalves FM, Freitas AE, Heinrich IA, Lopes MW, Leal RB, Rodrigues ALS (2018) Single administration of agmatine reverses the depressive-like behavior induced by corticosterone in mice: comparison with ketamine and fluoxetine. Pharmacol Biochem Behav 173:44–50
pubmed: 30125592
doi: 10.1016/j.pbb.2018.08.005
O’Leary OF, Felice D, Galimberti S et al (2014) GABAB(1) receptor subunit isoforms differentially regulate stress resilience. Proc Natl Acad Sci U S A 111:15232–15237
pubmed: 25288769
pmcid: 4210293
doi: 10.1073/pnas.1404090111
Oh DH, Son H, Hwang S, Kim SH (2012) Neuropathological abnormalities of astrocytes, GABAergic neurons, and pyramidal neurons in the dorsolateral prefrontal cortices of patients with major depressive disorder. Eur Neuropsychopharmacol 22:330–338
pubmed: 21962915
doi: 10.1016/j.euroneuro.2011.09.001
Parker GB, Graham RK (2015) Determinants of treatment-resistant depression: the salience of benzodiazepines. J Nerv Ment Dis 203:659–663
pubmed: 26241407
doi: 10.1097/NMD.0000000000000348
Patel MRBR, Kardile DP, Naik RA (2011) Agmatine inhibit the tolerance to the anxiolytic effect of diazepam in rats. Int J Pharm Appl Sci:44–51
Paxinos G, Franklin KBJ (2004) The mouse brain in stereotaxic coordinates. Elsevier Academic Press, Amsterdam
Petty F, Fulton M, Kramer GL, Kram M, Davis LL, Rush AJ (1999) Evidence for the segregation of a major gene for human plasma GABA levels. Mol Psychiatry 4:587–589
pubmed: 10578242
doi: 10.1038/sj.mp.4000569
Pigott HE, Leventhal AM, Alter GS, Boren JJ (2010) Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom 79:267–279
pubmed: 20616621
doi: 10.1159/000318293
Piletz JE, Aricioglu F, Cheng JT, Fairbanks CA, Gilad VH, Haenisch B, Halaris A, Hong S, Lee JE, Li J, Liu P, Molderings GJ, Rodrigues ALS, Satriano J, Seong GJ, Wilcox G, Wu N, Gilad GM (2013) Agmatine: clinical applications after 100 years in translation. Drug Discov Today 18:880–893
pubmed: 23769988
doi: 10.1016/j.drudis.2013.05.017
Post RM, Ketter TA, Joffe RT, Kramlinger KL (1991) Lack of beneficial effects of l-baclofen in affective disorder. Int Clin Psychopharmacol 6:197–207
pubmed: 1816278
doi: 10.1097/00004850-199100640-00001
Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough JW, Charney DS, Mathew SJ (2009) Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry 65:792–800
pubmed: 19058788
pmcid: 2934870
doi: 10.1016/j.biopsych.2008.10.025
Ren Z, Pribiag H, Jefferson SJ, Shorey M, Fuchs T, Stellwagen D, Luscher B (2016) Bidirectional homeostatic regulation of a depression-related brain state by gamma-aminobutyric acidergic deficits and ketamine treatment. Biol Psychiatry 80:457–468
pubmed: 27062563
pmcid: 4983262
doi: 10.1016/j.biopsych.2016.02.009
Rodrigues AL, Rocha JB, Mello CF, Souza DO (1996) Effect of perinatal lead exposure on rat behaviour in open-field and two-way avoidance tasks. Pharmacol Toxicol 79:150–156
pubmed: 8884874
doi: 10.1111/j.1600-0773.1996.tb00259.x
Rosa PB, Neis VB, Ribeiro CM, Moretti M, Rodrigues ALS (2016) Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors. Pharmacol Rep 68:996–1001
pubmed: 27423525
doi: 10.1016/j.pharep.2016.05.010
Sapkota K, Mao Z, Synowicki P, Lieber D, Liu M, Ikezu T, Gautam V, Monaghan DT (2016) GluN2D N-methyl-d-aspartate receptor subunit contribution to the stimulation of brain activity and gamma oscillations by ketamine: implications for schizophrenia. J Pharmacol Exp Ther 356:702–711
pubmed: 26675679
pmcid: 4767398
doi: 10.1124/jpet.115.230391
Sigel E, Ernst M (2018) The benzodiazepine binding sites of GABAA receptors. Trends Pharmacol Sci 39:659–671
pubmed: 29716746
doi: 10.1016/j.tips.2018.03.006
Spijker J, van Straten A, Bockting CL et al (2013) Psychotherapy, antidepressants, and their combination for chronic major depressive disorder: a systematic review. Can J Psychiatr 58:386–392
doi: 10.1177/070674371305800703
Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367–370
pubmed: 3923523
doi: 10.1007/BF00428203
Taksande BG, Kotagale NR, Patel MR, Shelkar GP, Ugale RR, Chopde CT (2010) Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats. Eur J Pharmacol 637:89–101
pubmed: 20394743
doi: 10.1016/j.ejphar.2010.03.058
Taksande BG, Sharma O, Aglawe MM, Kale MB, Gawande DY, Umekar MJ, Kotagale NR (2017) Acute orexigenic effect of agmatine involves interaction between central alpha2-adrenergic and GABAergic receptors. Biomed Pharmacother 93:939–947
pubmed: 28715875
doi: 10.1016/j.biopha.2017.07.004
Tavares MK, Dos Reis S, Platt N et al (2018) Agmatine potentiates neuroprotective effects of subthreshold concentrations of ketamine via mTOR/S6 kinase signaling pathway. Neurochem Int 118:275–285
pubmed: 29763645
doi: 10.1016/j.neuint.2018.05.006
Vasavada MM, Leaver AM, Espinoza RT, Joshi SH, Njau SN, Woods RP, Narr KL (2016) Structural connectivity and response to ketamine therapy in major depression: a preliminary study. J Affect Disord 190:836–841
pubmed: 26630613
doi: 10.1016/j.jad.2015.11.018
Wang HY, Kuo ZC, Fu YS, Chen RF, Min MY, Yang HW (2015) GABAB receptor-mediated tonic inhibition regulates the spontaneous firing of locus coeruleus neurons in developing rats and in citalopram-treated rats. J Physiol 593:161–180
pubmed: 25556794
doi: 10.1113/jphysiol.2014.281378
Wang DS, Penna A, Orser BA (2017) Ketamine increases the function of gamma-aminobutyric acid type A receptors in hippocampal and cortical neurons. Anesthesiology 126:666–677
pubmed: 27984263
doi: 10.1097/ALN.0000000000001483
Widman AJ, McMahon LL (2018) Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. Proc Natl Acad Sci U S A 115:3007–3016
doi: 10.1073/pnas.1718883115
Workman ER, Niere F, Raab-Graham KF (2013) mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling. Neuropharmacology 73:192–203
pubmed: 23752093
doi: 10.1016/j.neuropharm.2013.05.037
Yamamoto T, Nakayama T, Yamaguchi J, Matsuzawa M, Mishina M, Ikeda K, Yamamoto H (2016) Role of the NMDA receptor GluN2D subunit in the expression of ketamine-induced behavioral sensitization and region-specific activation of neuronal nitric oxide synthase. Neurosci Lett 610:48–53
pubmed: 26520463
doi: 10.1016/j.neulet.2015.10.049
Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864
pubmed: 16894061
doi: 10.1001/archpsyc.63.8.856
Zhang T, Du Y, Liu X et al (2019) Study on antidepressant-like effect of protoilludane sesquiterpenoid aromatic esters from Armillaria Mellea. Nat Prod Res:1–4
Zheng W, Xiao-Hong L, Xiao-Min Z et al (2019) Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials. J Affec Dis 250:123–131
Zomkowski ADE, Hammes L, Lin J, Calixto JB, Santos ARS, Rodrigues ALS (2002) Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 13:387–391
pubmed: 11930146
doi: 10.1097/00001756-200203250-00005
Zomkowski ADE, Rosa AO, Lin J et al (2004) Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res 1023:253–263
doi: 10.1016/j.brainres.2004.07.041